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ABSTRACT
Introduction: Continuous delivery of
levodopa–carbidopa intestinal gel (LCIG) by
percutaneous endoscopic gastrojejunostomy
(PEG-J) in advanced Parkinson’s disease (PD)
patients reduces variability in plasma levels,
providing better control of motor fluctuations
(‘‘on’’ and ‘‘off’’ states). The MONOTREAT study
assessed the effect of LCIG on activities of daily
living, motor and non-motor symptoms, and
quality of life in advanced PD patients.
Methods: This prospective, observational study
included patients with advanced, levodopa-re-
sponsive PD with either 2–4 h of ‘‘off’’ time or
2 h of dyskinesia daily. Patients received LCIG
via PEG-J for 16 h continuously. Effectiveness
was assessed using Unified PD Rating Scale parts
II and III, the Non-Motor Symptom Scale, and
the PD Questionnaire-8.
Results: The mean (SD) treatment duration was
275 (157) days. Patients experienced significant
improvement from baseline in activities of daily
living at final visit (p\0.05) as well as at
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months 3 and 6 (p\0.0001). Patients also
experienced significant improvements from
baseline in quality of life and non-motor
symptoms at all time points (p\0.001 for all).
Specifically, patients manifested significant
improvements in mean change from baseline at
every study visit in five of nine non-motor
symptom score domains: sleep/fatigue, mood/
cognition, gastrointestinal tract, urinary, and
miscellaneous. One-third of patients (32.8%)
experienced an adverse event; 21.9% experi-
enced a serious adverse event; 11.1% discon-
tinued because of an adverse event.
Conclusion: This study demonstrated signifi-
cant and clinically relevant improvements in
measures of activities of daily living, quality of
life, and a specific subset of non-motor symp-
toms after treatment with LCIG.
Funding: AbbVie Inc.
Keywords: Activities of daily living;
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disease; Percutaneous endoscopic
gastrojejunostomy; Quality of life
INTRODUCTION
Levodopa-related motor complications occur in
the majority of patients with Parkinson’s dis-
ease (PD) after 5–10 years of treatment [1]. The
motor complications are attributed to progres-
sive loss of striatal dopamine nerve terminals,
the short half-life of levodopa, as well as vari-
able gastric emptying and intestinal absorption
leading to irregular plasma levodopa levels
[2, 3].
In addition, patients manifest non-motor
symptoms (e.g., cognitive deficits, sleep
abnormalities, autonomic dysfunction), which
can greatly impair a patient’s autonomy,
resulting in increasing caregiver support and
reduced quality of life. The prevalence of
non-motor symptoms increases with disease
severity but varies among the different domains
and is patient specific [4, 5]. Several studies
reported a strong contribution of non-motor
symptoms on quality of life, confirming their
relevance as therapeutic targets [4, 6–8].
Levodopa–carbidopa intestinal gel [LCIG,
Duodopa, carbidopa levodopa enteral suspen-
sion in the USA (CLES, Duopa), AbbVie Inc,
North Chicago, IL, USA] is continuously deliv-
ered via percutaneous endoscopic gastroje-
junostomy (PEG-J) in patients with advanced
PD who have motor fluctuations and dyskinesia
not adequately managed by available orally
administered anti-Parkinsonian medications.
Continuous delivery by PEG-J reduces variabil-
ity in plasma levels by avoiding the effects of
erratic gastric emptying [9]. This strategy redu-
ces ‘‘off’’ time and improves quality of life in
patients with advanced PD in a controlled set-
ting [6, 10–14]. Previous studies have reported
extensively on the safety and efficacy of LCIG in
controlled settings; however, there is a dearth of
‘‘real-life’’ data available on the use of LCIG in
clinical practice. Further, these studies have
typically included patients with advanced PD as
well as long disease duration. The objective of
this study was to assess the effect of LCIG
treatment on activities of daily living, motor
and non-motor symptoms, and quality of life in
patients as they start presenting with motor
complications.
METHODS
Patients
Patients were eligible to participate in the study
if they fulfilled the following criteria at baseline:
patients were diagnosed with advanced,
levodopa-responsive PD; patients’ physicians
chose to use LCIG to treat patients’ PD in
accordance with the local approved use before
any decision was made to solicit a patient’s
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participation in this study; patients had
unchanged PD treatment for at least 4 weeks
before the baseline visit; patients received four
or more daily oral doses of PD medication; and
patients had 2–4 h of ‘‘off’’ time or 2 h of
non-troublesome or troublesome dyskinesia
daily supported by a Unified Parkinson’s Disease
Rating Scale (UPDRS) total score in the best ‘‘on’’
state of at least 40 points at baseline [15, 16].
Patients were excluded if they had been treated
with deep brain stimulation (DBS), used apo-
morphine pump, received LCIG treatment
before the baseline visit, or had evidence for
clinically relevant cognitive deficits, as defined
by a score less than 24 on the mini-mental state
examination.
Study Design and Treatment
This prospective, post-marketing observational
study was performed in an international, mul-
ticenter setting at 30 sites. There were five target
visits: baseline; hospital discharge; and months
3, 6, and 12 after hospital discharge. A tempo-
rary naso-jejunal tube was used for LCIG
administration to determine if the patient
responded favorably to LCIG and to optimize
the dose before treatment was initiated via
PEG-J tube. LCIG was administered directly into
the proximal small intestine through a jejunal
extension tube using a portable infusion pump.
Patients who chose not to continue LCIG
treatment after the temporary naso-jejunal test
phase as well as patients who discontinued
LCIG treatment during the study had the
option to continue the study in the stan-
dard-of-care group (orally and/or transdermally
administered anti-Parkinson’s disease medica-
tions that patients were taking prior to consid-
eration for LCIG treatment). If, during the
study, a patient chose to be treated with apo-
morphine pump or DBS, the patient was no
longer eligible to continue in the study. This
study was conducted in accordance with the
principles of the Declaration of Helsinki of
1964, as revised in 2013, good clinical practice,
and applicable local legal and regulatory
requirements. All patients provided written
informed consent.
Assessments
Effectiveness
The primary endpoint was the change from
baseline to final visit in a patient’s impairment in
activities of daily living as measured by UPDRS
Part II (score range 0–52; a higher score indicates
a greater impairment; measured during the best
‘‘on’’ time). Secondary endpoints included the
change from baseline in activities of daily living
at other time points; UPDRS Part III and IV scores
(measured during the best ‘‘on’’ time), scores on
the Parkinson’s Disease Questionnaire-8 (PDQ-8)
summary index (assessing quality of life; score
normalized to a scale of 0–100, with a higher
summary index indicating a greater impair-
ment); and scores on the Non-Motor Symptoms
Scale (NMSS) and subdomains, which assessed
non-motor symptoms over the previous month
(total NMSS score range 0–360, with a higher
score indicating more severe symptoms).
Safety
Safety was assessed by adverse events (AEs) and
product complaints. Investigators identified the
severity and seriousness of AEs, and indicated
their opinion of the relationship of the AE to
LCIG (reasonable possibility or not).
Statistical Analysis
All statistical analyses were performed using SAS
version 9.2 (SAS Institute, Inc., Cary, NC, USA).
Significant changes from baseline in the LCIG
group were assessed using two-sided t tests. ‘‘Final’’
endpoints included data from month 12 with the
last observation carried forward for missing val-
ues. The standard-of-care treatment group was
not powered for statistical analysis; as such, sta-
tistical comparisons were not made within the
standard-of-care treatment group nor between
the standard of care and LCIG treatment groups.
RESULTS
Patients
Patient baseline characteristics are shown in
Table 1. The majority of patients in this study
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were male, and the average age was 70.4 (7.8)
years. The average PD duration was 13.9 (5.4)
years and the most common previous PD ther-
apies were orally administered levodopa (100%)
and dopamine agonists (94%).
Overall, 65 patients were screened and 64
patients began treatment via naso-jejunal tube
(Fig. 1). One patient was excluded because of a
protocol violation. A total of 58 (89%)
continued to LCIG treatment via PEG-J after the
initial naso-jejunal test phase. Six (9%) patients
returned to the standard-of-care group after
starting LCIG therapy via a naso-jejunal tube
and prior to PEG-J placement (please see Sup-
plemental Table 1 for detailed patient disposi-
tion by visit).
The mean (SD) study duration was 308 (129)
days (range 1–546 days); the mean (SD) LCIG
treatment duration was 275 (157) days (range
2–545 days). Forty-one patients (63%) com-
pleted all 12 months of LCIG treatment. Over
the course of the study, 16 patients (25%)
switched to the standard-of-care group (orally
and/or transdermally administered dopaminer-
gic therapy), although only six remained in the
standard-of-care group through month 12. Of
patients who did not remain in the stan-
dard-of-care group, one patient opted for an
excluded surgical treatment and nine patients
discontinued participation in the study (or
there was no treatment information).
A total of 23 patients (35.9%) discontinued
LCIG treatment during the study, most com-
monly by patients’ decision (nine patients,
14.1%), or by the investigator as a result of a
medical event (eight patients, 12.5%) (please
see Supplemental Table 2 for reasons for
discontinuation).
Effectiveness
LCIG Treatment Group
In patients receiving LCIG, there was a signifi-
cant improvement from baseline in patients’
abilities to perform activities of daily living
(UPDRS Part II) at the final visit [mean (SD)
change from baseline of -2.1 (6.9); p\0.05]
(Fig. 2). Results were also significant at months 3
and 6 (p\0.0001); an improvement of-1.8 (7.1)
from baseline at month 12 was not significant.
Patients receiving LCIG experienced signifi-
cant improvements from baseline in motor
symptoms at all time points, as measured by
UPDRS Part III total score (p\0.0001 at all time
points, Fig. 3a). The largest improvement from
baseline was seen after 3 months of treatment
[mean (SD) change from baseline of -12.9
(16.2)]; improvements from baseline were
Table 1 Baseline demographics and disease characteristics
Parameter n5 64
Mean (SD) age, years 70.4 (7.8)
Sex, n (%)
Male 39 (61)
Female 25 (39)
Mean (SD) PD duration, years 13.9 (5.4)
Previous PD therapy, n (%)
Orally administered levodopa 64 (100)
Orally administered dopamine agonist 60 (94)
COMT inhibitor 45 (70)
MAO-B inhibitor 38 (59)
Amantadine 31 (48)
Rotigotine 25 (39)
Apomorphine, sc 12 (19)
Mean (SD) UPDRS Part II total scorea 18.1 (8.0)
Mean (SD) UPDRS Part III total scorea 36 (16.2)
Mean (SD) UPDRS Part IV scorea
Item 32 1.4 (1.1)
Item 33 1.4 (1.3)
Item 34 0.6 (0.9)
Mean (SD) PDQ-8 summary index 48.6 (16.2)
Mean (SD) NMSS total score 95.5 (54.5)
SD standard deviation, PD Parkinson’s disease, COMT
catechol-O-methyltransferase, MAO-B monoamine oxi-
dase-B, sc subcutaneous, UPDRS Uniﬁed Parkinson’s
Disease Rating Scale, PDQ-8 Parkinson’s Disease Ques-
tionnaire-8 item, NMSS Non-Motor Symptoms Scale
a UPDRS was measured during patients’ best ‘‘on’’ time
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around -9 thereafter. Patients receiving LCIG
had a significant mean decrease from baseline
in the PDQ-8 summary index score at all time
points (p\0.0001 at month 3 and 6; p\0.001
at month 12 and final; Fig. 3b). The mean
change in the NMSS total score from baseline
was significant at every time point in patients
receiving LCIG (p\0.0001), indicating that the
significant improvement in non-motor symp-
toms was sustained over time (Fig. 3c). Patients
manifested significant improvements in the
mean change from baseline at every study visit
in five of the nine NMSS domains: sleep/fatigue,
mood/cognition, gastrointestinal tract, urinary,
and miscellaneous (Table 2).
Standard-of-Care Treatment Group
Patients in the standard-of-care group demon-
strated small improvements from baseline of
-1.5 (2.3) in UPDRS Part II total score at month
6, although the mean change from baseline at
month 12 of 0.5 (5.3) indicates that there was
no improvement from baseline at month 12 in
the standard-of-care group (Supplemental
Fig. 1A). Patients in the standard-of-care group
also experienced some improvement from
baseline in UPDRS Part III total score at months
3, 6, and at the final measurement (Supple-
mental Fig. 1B). Patients in the standard-of-care
group experienced reductions from baseline in
PDQ-8 summary index scores and numeri-
cal/formal improvements from baseline in
non-motor symptoms at all time points (Sup-
plemental Fig. 1C, D). Patients experienced
improvements at each visit in four of nine
NMSS subdomains: cardiovascular, mood/cog-
nition, gastrointestinal, and miscellaneous
(Supplemental Table 3). The small number of
Fig. 1 Patient disposition from enrollment to day 1 post PEG-J placement. LCIG levodopa–carbidopa intestinal gel,
PEG-J percutaneous endoscopic gastrojejunostomy
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patients in the standard-of-care group did not
allow for any statistical analyses.
Safety
One-third of the patients (32.8%) experienced
an AE. Eight patients (12.7%) experienced AEs
that were considered to be possibly related to
LCIG, as rated by the study investigator.
Adverse events occurring in two or more
patients included stoma site infection (4.7%),
therapy cessation (4.7%), and psychotic disor-
der (3.1%). Of the 14 patients (21.9%) who
experienced a serious AE, two patients (3.1%)
experienced a psychotic disorder. Two patients
(3.1%) experienced serious AEs reported by the
study investigator to have a reasonable possi-
bility of being related to the treatment: one
patient had dopamine dysregulation syndrome,
overdosed on orally administered levodopa/en-
tacapone, suffered psychosis, and was hospital-
ized; the other patient had a mild lung infection
and severe dystonia of both legs. Two patients
(3.1%) died during the study (causes of death:
cardiac failure and sudden death); both deaths
were deemed by the investigator as having no
reasonable possibility of being related to LCIG.
Seven patients (11.1%) discontinued LCIG
treatment because of AEs, including one of each
of the following AEs: peristomal fasciitis, peri-
tonitis, gastrostomy tube infection, dopamin-
ergic dysregulation syndrome, severe dystonia,
lack of clinical improvement, and a severed
tube. Three AEs (stoma site infection, peris-
tomal granuloma and gastric secretion, and
peristomal fasciitis) were associated with three
different product complaints and were reported
in one patient each.
DISCUSSION
Results from this prospective, multicenter,
observational study showed significant
improvements in activities of daily living,
Fig. 2 Mean (SD) change from baseline in measures of
activities of daily living in the LCIG treatment group.
Activities of daily living were measured by UPDRS Part II
total score during the best ‘‘on’’ time. Statistical signiﬁcance
compared with baseline is indicated at p B 0.05 (single
asterisk) and p B 0.0001 (triple asterisk). ‘‘Final’’ is the last
observation carried forward. LCIG levodopa–carbidopa
intestinal gel, UPDRS Uniﬁed Parkinson’s Disease Rating
Scale
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motor and non-motor symptoms, and qual-
ity-of-life scores, with safety results in accord
with the known safety profile of LCIG
[11, 12, 17]. These results extend current find-
ings, which have focused primarily on the effect
of LCIG on motor complications [10–12, 14]. As
it has recently been suggested that there is a
relationship between improvements in motor
UPDRS and NMSS scores [18], assessing the
effect of both motor and non-motor symptoms
on quality of life will be a boon to patients with
advanced PD.
General disease progression and gradual
deterioration of activities of daily living have
been reported to occur at an average yearly
decline in UPDRS Part II scores of 0.56 (mea-
sured during ‘‘on’’ time) [19]. In the current
study, LCIG treatment led to significant
improvements in patients’ activities of daily
living from baseline to the final visit (primary
endpoint), and at 3 and 6 months after starting
LCIG therapy. The minimal clinically important
difference in UPDRS part II scores has been
previously determined to be 1.8 [15]; results
from the current study indicated improvements
of 1.8 or more as observed at all time points.
Patients treated with LCIG also experienced
significant improvements from baseline in
motor symptoms at each time point. The
greatest improvement in UPDRS Part III scores
Fig. 3 Mean (SD) change from baseline in measures of
a motor symptoms, b quality of life, and c non-motor
symptoms in the LCIG treatment group. Motor symptoms
were measured by UPDRS Part III total score during the
best ‘‘on’’ time; quality of life was measured by PDQ-8
summary index score; non-motor symptoms were mea-
sured using the NMSS total score. Statistical signiﬁcance
compared with baseline is indicated at p B 0.01 (double
asterisk) and p B 0.0001 (triple asterisk). ‘‘Final’’ is the last
observation carried forward. LCIG levodopa–carbidopa
intestinal gel, NMSS Non-Motor Symptom Scale, PDQ-8
Parkinson’s disease questionnaire, UPDRS Uniﬁed Parkin-
son’s Disease Rating Scale
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was -12.9 at month 3; improvements in motor
skills were sustained around -9 for the
remainder of the study. The minimal clinically
important difference in UPDRS part III scores
has been previously reported to be 2.5 points,
with moderate improvement classified as 5.2
points, and large improvement at 10.8 points
[20]. On the basis of these criteria, patients in
this study experienced moderate-to-large clini-
cally important improvements in motor
symptoms.
Non-motor symptoms have been shown to
negatively impact quality of life in both patients
and caregivers [4, 6–8, 21]. However, non-motor
symptoms are frequently not well recognized
and assessed in clinical practice [22]. In this
study, patients treated with LCIG experienced
significant improvements from baseline in
non-motor symptoms, with corresponding
improvements in quality of life (as measured by
PDQ-8), at all time points. Overall improve-
ments from baseline in quality of life and
non-motor symptoms were similar to those
reported in other observational, routine-care
studies [23, 24]. Patients experienced significant
improvements from baseline for sleep/fatigue,
mood/cognition, gastrointestinal tract, urinary,
and miscellaneous NMSS subscores. LCIG
treatment has previously demonstrated a varied
degree of significant improvement in these
same subdomains in other studies [6, 23–25].
When compared with results in other studies
assessing non-motor symptoms in patients
receiving LCIG, patients in the current study
exhibited greater improvements in mood/cog-
nition, less improvement in sleep/fatigue, and
improvements in gastrointestinal and urinary
symptoms in between the improvements seen
in other studies [6, 23]. Patients treated with
DBS have demonstrated significant improve-
ment in NMSS total score and six of nine sub-
domains, although improvements in these
patients were generally of smaller magnitude
than in the current study (except for sleep/fa-
tigue) [26], which may account for the larger
improvements in quality of life experienced by
patients undergoing LCIG treatment. Treat-
ment with apomorphine infusion has also
Table 2 Change from baseline in NMSS domain scores in the LCIG treatment group
NMSS domain Visit, mean (SD)
Month 3
(n5 44)
Month 6
(n5 40)
Month 12
(n 5 38)
Final
(n5 40)
Cardiovascular including falls -1.7 (4.3)a -0.8 (3.0) -0.8 (3.3) -0.7 (3.2)
Sleep/fatigue -6.8 (8.7)d -5.9 (8.0)d -5.6 (8.9)c -5.4 (8.7)c
Mood/cognition -7.8 (14.3)c -7.6 (13.5)b -8.8 (13.9)c -8.4 (13.7)c
Perceptual problems/hallucinations -1.1 (4.1) -1.5 (4.2)a -2.0 (5.0)a -1.9 (4.9)a
Attention/memory -2.1 (8.0) -1.3 (8.3) -1.8 (7.8) -1.9 (7.7)
Gastrointestinal tract -5.7 (6.4)d -4.4 (6.7)c -3.8 (6.4)c -3.8 (6.3)c
Urinary -7.4 (10.7)d -5.9 (10.5)b -5.9 (9.9)c -5.5 (9.9)b
Sexual function -1.3 (6.4) -0.5 (5.7) -0.3 (7.2) -0.2 (7.0)
Miscellaneous -5.7 (9.5)c -5.9 (8.4)d -4.9 (9.5)b -4.7 (9.3)b
‘‘Final’’ represents the last observation carried forward
LCIG levodopa–carbidopa intestinal gel, NMSS Non-Motor Symptom Scale, SD standard deviation
a p\0.05
b p\0.01
c p\0.001
d p\0.0001
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demonstrated significant improvements in
NMSS total score and in six of nine subdomains;
improvements in urinary function were not to
the same degree as noted in the current study
[24]. Among the variety of non-motor symp-
toms observed in PD patients, it was recently
shown that mood was consistently among the
most important predictors for an impact on
quality of life [21, 27, 28], which further
underscores the relevance of the observed
greater improvement in mood/cognition in the
present study.
Individuals in the standard-of-care treatment
group did show some numerical/formal and/or
transient improvements from baseline in activ-
ities of daily living, quality of life, and
non-motor symptoms. However, the size of the
standard-of-care group was small, and the size
fluctuated over the course of the study, as
patients could switch to the standard-of-care
group at any time during the study. Conse-
quently, patients who may have initially been
treated with LCIG before switching to the
standard of care may have altered the outcomes
in the standard-of-care group. Further, the
variability and small size of the standard-of-care
group precluded any statistical analyses and any
comparisons between groups.
The safety results were consistent with the
established safety profile of LCIG [11, 12, 17];
no new safety concerns were reported or
detected. The most common AEs were related to
maintenance of the stoma site. It has been
reported that there is considerable potential for
gastrointestinal serious adverse events with
LCIG treatment [29]; however, in this study,
there was only one incident of peritonitis, and
all gastrointestinal serious adverse events were
not considered to be related to the treatment. In
addition, axonal neuropathy has been reported
in patients treated with LCIG [30]; however,
there were no reports of neuropathy in the
current study. Although there was a relatively
high (35.9%) overall rate of discontinuation
from LCIG treatment, in only 11.1% of patients
it was due to AEs.
Interestingly, patients in this study tended to
be older (mean age of 70.4 vs. 64 years) and
have a longer disease duration (mean duration
of 14 vs. 12.5 years) than patients in a previous
open-label study, despite similar inclusion cri-
teria [11]. Moreover, the magnitude of
improvement of activities of daily living (as
assessed by UPDRS II) was smaller than previ-
ously reported (-2.1 vs. -4.4). The observed
older age of patients included in the present
study could have an impact on the treatment
response and benefit, as it has been shown for
other interventional therapies [31, 32].
A limitation of this study design is that the
effectiveness measures were based on self-re-
ported assessments and did not include a diary
to assess motor benefit. Because this study was
conducted as an observation of routine care
with LCIG, these outcomes are considered to be
close to what may be observed in real-world
clinical practice. Nonetheless, this study was
limited by the observational design and the lack
of a true control group. Because patients in the
standard-of-care group could have initiated
LCIG before they decided to transition back to
standard-of-care treatment (and also back to
LCIG), no direct comparisons or statistical
analyses can be made between the groups. Fur-
ther prospective randomized controlled studies
are needed to assess the differences between
LCIG and standard of care in activities of daily
living, non-motor symptoms, and quality of
life.
CONCLUSION
This study demonstrated significant and clini-
cally relevant improvements in measures of
activities of daily living, motor and non-motor
symptoms, and quality of life after treatment
with LCIG. Despite a relatively high rate of
discontinuation, these data indicate that in
addition to the previously reported safety and
efficacy, LCIG also provides significant benefits
to activities of daily living, non-motor symp-
toms, and quality of life in patients with
advanced PD.
ACKNOWLEDGEMENTS
Financial support for this study, as well as
funding for the article processing charges and
Adv Ther
open access fee associated with this manuscript,
was provided by AbbVie Inc., North Chicago, IL,
USA. All authors had full access to all of the data
in this study and take complete responsibility
for the integrity of the data and accuracy of the
data analysis.
All named authors meet the International
Committee of Medical Journal Editors (ICMJE)
criteria for authorship for this manuscript, take
responsibility for the integrity of the work as a
whole, and have given final approval for the ver-
sion to be published. Rejko Kru¨ger, Paul Lingor,
Triantafyllos Doskas, Johanna Henselmans, Erik
H. Danielsen, Oriol de Fabregues, Alessandro Ste-
fani, Koray Onuk, and Angelo Antonini acquired
and interpreted the data and reviewed and cri-
tiqued the manuscript throughout the editorial
process. Sven-Christian Sensken, Juan Carlos
Parra, and Ashley Yegin were responsible for
original research project conception and design,
and reviewed and critiqued the manuscript
throughout the editorial process. Juan Carlos
Parra also performed statistical analysis. Data
included in this manuscript were previously pre-
sented at the 20th International Congress of
Parkinson’s Disease and Movement Disorders,
June 19–21, 2016, in Berlin, Germany, at the 11th
International Congress on Non-Motor Dysfunc-
tions in Parkinson’s Disease and Related Disorders,
October 6–8, 2016, in Ljubljana, Slovenia, as well
as at the Austrian Parkinson Society (O¨PG) Annual
Meeting, October 20–22, 2016, in Graz, Austria.
Medical writing assistance was provided by
Kelly M. Cameron, PhD, of JB Ashtin, who, on
behalf of AbbVie Inc., helped prepare the first
draft and implemented author revisions
throughout the editorial process. Support for
this assistance was funded by AbbVie Inc.
Disclosures. Rejko Kru¨ger was a study
investigator. He has received research grants
from the German Research Council (DFG:
KR2119/8-1), the Michael J Fox Foundation, the
Fritz Thyssen Foundation (10.11.2.153), the
Federal Ministry for Education and Research
(BMBF, NGFNplus; 01GS08134), the Fonds
National de Recherche Luxembourg (FNR;
PEARL and NCER-PD), and from the European
Union’s Horizon 2020 research and innovation
program under grant agreement No. 692320
(TWINNING; Centre-PD). He has received
speakers’ honoraria and/or travel grants from
UCB Pharma, AbbVie, Takeda Pharmaceuticals,
St Jude, and Medtronic. Paul Lingor was a study
investigator and received speaker honoraria
and/or travel grants from AbbVie, Licher MT,
Medtronic, BayerVital, and Zambon. His
research has been supported by the German
Research Council (DFG), the Michael J Fox
Foundation, and the Else Kro¨ner-Fresenius Stif-
tung. Triantafyllos Doskas was a study investi-
gator, and has received speaker/consulting
honoraria from Merck, Novartis, Teva, Actel-
lion, and Genesis. Erik H Danielsen was a study
investigator and has no other conflicts of
interest to disclose. Alessandro Stefani was a
study investigator and has no other conflicts of
interest to disclose. Johanna Henselmans was a
study investigator and did not receive any per-
sonal funding from AbbVie over the past year.
Oriol de Fabregues was a study investigator and
has received speaker honoraria from AbbVie
and Zambon; he reports no other financial
conflicts of interest. Sven-Christian Sensken is
an employee of AbbVie Deutschland GmbH &
Co KG. Juan Carlos Parra is an employee of
AbbVie Inc, and holds AbbVie stock and/or
stock options. Koray Onuk is an employee of
AbbVie Inc, and holds AbbVie stock and/or
stock options. Ashley Yegin is an employee of
AbbVie Inc, and holds AbbVie stock and/or
stock options. Angelo Antonini has received
honoraria for consulting services and symposia
from AbbVie. This study was funded by AbbVie
Inc. AbbVie participated in the study design,
research, data collection, analysis, and inter-
pretation of data, writing, reviewing, and
approving the manuscript for publication.
Compliance with Ethics Guidelines. All
procedures followed were in accordance with
the ethical standards of the responsible com-
mittee on human experimentation (institu-
tional and national) and with the Helsinki
Declaration of 1964, as revised in 2013.
Informed consent was obtained from all
patients for being included in the study.
Data Availability. The clinical study report
synopsis is available on AbbVie.com. Requests
Adv Ther
for additional trial data can be made at http://
abbvie.com.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/
by-nc/4.0/), which permits any noncommercial
use, distribution, and reproduction in any
medium, provided you give appropriate credit
to the original author(s) and the source, provide
a link to the Creative Commons license, and
indicate if changes were made.
REFERENCES
1. Ahlskog JE, Muenter MD. Frequency of
levodopa-related dyskinesias and motor fluctua-
tions as estimated from the cumulative literature.
Mov Disord. 2001;16(3):448–58.
2. Hardoff R, Sula M, Tamir A, et al. Gastric emptying
time and gastric motility in patients with Parkin-
son’s disease. Mov Disord. 2001;16(6):1041–7.
3. Contin M, Martinelli P. Pharmacokinetics of levo-
dopa. J Neurol. 2010;257(Suppl 2):S253–61.
4. Martinez-Martin P, Schapira AH, Stocchi F, et al.
Prevalence of nonmotor symptoms in Parkinson’s
disease in an international setting; study using
nonmotor symptoms questionnaire in 545 patients.
Mov Disord. 2007;22(11):1623–9.
5. Antonini A, Barone P, Marconi R, et al. The pro-
gression of non-motor symptoms in Parkinson’s
disease and their contribution to motor disability
and quality of life. J Neurol. 2012;259(12):2621–31.
6. Honig H, Antonini A, Martinez-Martin P, et al.
Intrajejunal levodopa infusion in Parkinson’s dis-
ease: a pilot multicenter study of effects on non-
motor symptoms and quality of life. Mov Disord.
2009;24(10):1468–74.
7. Estrada-Bellmann I, Camara-Lemarroy CR,
Calderon-Hernandez HJ, Rocha-Anaya JJ, Vil-
lareal-Velazquez HJ. Non-motor symptoms and
quality of life in patients with Parkinson’s disease in
Northeastern Mexico. Acta Neurol Belg.
2016;116(2):157–61.
8. Santos-Garcia D, de la Fuente-Fernandez R. Impact
of non-motor symptoms on health-related and
perceived quality of life in Parkinson’s disease.
J Neurol Sci. 2013;332(1–2):136–40.
9. Othman AA, Chatamra K, Mohamed ME, et al.
Jejunal Infusion of levodopa–carbidopa intestinal
gel versus oral administration of levodopa–car-
bidopa tablets in Japanese subjects with advanced
Parkinson’s disease: pharmacokinetics and pilot
efficacy and safety. Clin Pharmacokinet.
2015;54(9):975–84.
10. Olanow CW, Kieburtz K, Odin P, et al. Continuous
intrajejunal infusion of levodopa–carbidopa
intestinal gel for patients with advanced Parkin-
son’s disease: a randomised, controlled, dou-
ble-blind, double-dummy study. Lancet Neurol.
2014;13(2):141–9.
11. Fernandez HH, Standaert DG, Hauser RA, et al.
Levodopa–carbidopa intestinal gel in advanced
Parkinson’s disease: final 12-month, open-label
results. Mov Disord. 2015;30(4):500–9.
12. Slevin JT, Fernandez HH, Zadikoff C, et al. Long-
term safety and maintenance of efficacy of
levodopa–carbidopa intestinal gel: an open-label
extension of the double-blind pivotal study in
advanced Parkinson’s disease patients. J Parkinsons
Dis. 2015;5(1):165–74.
13. Puente V, De Fabregues O, Oliveras C, et al. Eigh-
teen month study of continuous intraduodenal
levodopa infusion in patients with advanced
Parkinson’s disease: impact on control of fluctua-
tions and quality of life. Parkinsonism Relat Disord.
2010;16(3):218–21.
14. Antonini A, Fung VS, Boyd JT, et al. Effect of
levodopa–carbidopa intestinal gel on dyskinesia in
advanced Parkinson’s disease patients. Mov Disord.
2016;31(4):530–7.
15. Hauser RA, Gordon MF, Mizuno Y, et al. Minimal
clinically important difference in Parkinson’s dis-
ease as assessed in pivotal trials of pramipexole
extended release. Parkinsons Dis.
2014;2014:467131.
16. Hauser RA, Auinger P, Parkinson Study Group.
Determination of minimal clinically important
change in early and advanced Parkinson’s disease.
Mov Disord. 2011;26(5):813–8.
17. LangAE,RodriguezRL,BoydJT, etal. Integratedsafety
of levodopa–carbidopa intestinal gel from prospective
clinical trials. Mov Disord. 2016;31(4):538–46.
18. Muller T, Ohm G, Eilert K, et al. Benefit on motor
and non-motor behavior in a specialized unit for
Parkinson’s disease. J Neural Transm (Vienna).
2017;124(6):715–20.
19. Jankovic J, Kapadia AS. Functional decline in
Parkinson disease. Arch Neurol.
2001;58(10):1611–5.
Adv Ther
20. Shulman LM, Gruber-Baldini AL, Anderson KE,
Fishman PS, Reich SG, Weiner WJ. The clinically
important difference on the unified Parkinson’s
disease rating scale. Arch Neurol. 2010;67(1):64–70.
21. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis
MM, Chaudhuri KR, NMSS Validation Group. The
impact of non-motor symptoms on health-related
quality of life of patients with Parkinson’s disease.
Mov Disord. 2011;26(3):399–406.
22. Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, et al.
The nondeclaration of nonmotor symptoms of
Parkinson’s disease to health care professionals: an
international study using the nonmotor symptoms
questionnaire. Mov Disord. 2010;25(6):704–9.
23. Antonini A, Yegin A, Preda C, et al. Global long-
term study on motor and non-motor symptoms
and safety of levodopa–carbidopa intestinal gel in
routine care of advanced Parkinson’s disease
patients; 12-month interim outcomes. Parkinson-
ism Relat Disord. 2015;21(3):231–5.
24. Martinez-Martin P, Reddy P, Katzenschlager R, et al.
EuroInf: a multicenter comparative observational
study of apomorphine and levodopa infusion in
Parkinson’s disease. Mov Disord. 2015;30(4):510–6.
25. Reddy P, Martinez-Martin P, Rizos A, et al. Intraje-
junal levodopa versus conventional therapy in
Parkinson disease: motor and nonmotor effects.
Clin Neuropharmacol. 2012;35(5):205–7.
26. Dafsari HS, Reddy P, Herchenbach C, et al. Benefi-
cial effects of bilateral subthalamic stimulation on
non-motor symptoms in Parkinson’s disease. Brain
Stimul. 2016;9(1):78–85.
27. Prakash KM, Nadkarni NV, Lye WK, Yong MH, Tan
EK. The impact of non-motor symptoms on the
quality of life of Parkinson’s disease patients: a
longitudinal study. Eur J Neurol.
2016;23(5):854–60.
28. Liu WM, Lin RJ, Yu RL, Tai CH, Lin CH, Wu RM.
The impact of nonmotor symptoms on quality of
life in patients with Parkinson’s disease in Taiwan.
Neuropsychiatr Dis Treat. 2015;11:2865–73.
29. Klostermann F, Jugel C, Bomelburg M, Marzinzik F,
Ebersbach G, Muller T. Severe gastrointestinal
complications in patients with levodopa/carbidopa
intestinal gel infusion. Mov Disord.
2012;27(13):1704–5.
30. Jugel C, Ehlen F, Taskin B, Marzinzik F, Muller T,
Klostermann F. Neuropathy in Parkinson’s disease
patients with intestinal levodopa infusion versus
oral drugs. PLoS One. 2013;8(6):e66639.
31. Bouwyn JP, Derrey S, Lefaucheur R, et al. Age limits
for deep brain stimulation of subthalamic nuclei in
Parkinson’s disease. J Parkinsons Dis.
2016;6(2):393–400.
32. Derost PP, Ouchchane L, Morand D, et al. Is
DBS-STN appropriate to treat severe Parkinson dis-
ease in an elderly population? Neurology.
2007;68(17):1345–55.
Adv Ther
